QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Reports 2025 Financial Results and Clinical Progress for GelrinC(R)
Regentis Biomaterials (NYSE American: RGNT) reported financial results for the year ended Dec. 31, 2025, and provided a corporate and clinical update highlighting progress in its pivotal Phase III study of GelrinC(R) for knee cartilage repair. The company said its strengthened balance sheet, with more than $7 million in cash following its IPO, is expected to support completion of patient recruitment and treatment in the Phase III trial by mid-2026, while also providing runway to begin commercial marketing efforts for GelrinC(R) in Europe. To view the full press release, visit https://ibn.fm/ewdqz About Regentis Biomaterials Regentis Biomaterials Ltd is a regenerative…